Clinical Benefits of Tezepelumab in a Real-World Cohort of Patients With Severe Uncontrolled Asthma in Castilla-La Mancha, Spain.

Introduction: Tezepelumab is an anti-thymic stromal lymphopoietin monoclonal antibody approved for the treatment of severe uncontrolled asthma regardless of inflammatory phenotype. Although its efficacy has been demonstrated in clinical trials, there is a growing need to evaluate its effectiveness in real-world clinical practice in Spain. The aim of this study was to evaluate the clinical impact of tezepelumab in patients with severe asthma treated in 5 hospitals in Castilla-La Mancha, Spain. Material and methods: This was a retrospective multicenter observational study. Adult patients with severe asthma treated with tezepelumab were included between January 2023 and April 2025. Clinical, functional, and laboratory parameters were evaluated between the 6-month baseline period (before treatment initiation) and the follow-up visit. Exacerbations, asthma control test (ACT), lung function (forced expiratory volume in 1 second [FEV Results: A total of 48 patients were included (mean age 52.8 years; 70.8% women). The mean number of exacerbations decreased significantly from 2.06 to 0.22 per patient ( Conclusions: Tezepelumab was shown to be effective in real-world clinical practice, achieving a significant improvement in severe asthma control and lung function, while reducing exacerbations and oral corticosteroid use.